Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Marc Bonnay"'
Autor:
Sandrine Faivre, Arno Nolting, Jean-Claude Vedovato, M. Mueser, Marc Bonnay, Eric Raymond, Véronique Diéras, Valérie Laurence, Jean-Yves Pierga, Andreas Kovar, Catherine Delbaldo
Publikováno v:
European Journal of Cancer. 41:1739-1745
This trial assessed pharmacokinetic interactions between cetuximab and irinotecan. Patients were placed in either in group A (irinotecan 350 mg/m2/3 weeks and 400 mg/m2 cetuximab at week 2 then 250 mg/m2/week) or group B (cetuximab weekly starting we
Autor:
Lluis M. Mir, Gregor Sersa, Maja Cemazar, J. Belehradek, Marc Bonnay, Damijan Miklavčič, D Fourcault
Publikováno v:
European Journal of Cancer. 37:1166-1172
The aim of the study was to determine whether electrochemotherapy with cisplatin could be implemented in treatment of cisplatin-resistant solid tumours. For this purpose, we used cisplatin-sensitive TBL.Cl2 cells and their cisplatin-resistant subclon
Autor:
R Bonacci, Eric Baudin, Marc Bonnay, P Emy, A. F. Cailleux, N Wion-Barbot, M. Schlumberger, I Nakib, A Gigliotti
Publikováno v:
British Journal of Cancer. 78:546-549
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 m
Autor:
M Mahjoubi, Marc Bonnay, G. Bastian, C. Cote, R. Hagipantelli, Dominique Mignard, Esteban Cvitkovic, Patrice Herait, Gilles Vassal, J. L. Misset, F. Saliba
Publikováno v:
Journal of Clinical Oncology. 16:2745-2751
PURPOSE Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset dia
Autor:
Christine Theodore, Claudine Korenbaum, François Blot, Bertrand Gachot, Arnaud de Lassence, Gérard Nitenberg, Marc Bonnay, Vincent Ribrag, Lucyna Kepka
Publikováno v:
Leukemia & Lymphoma. 29:205-209
We describe the case of a 35-year old male who developed acute renal failure following high dose methotrexate therapy for Burkitt's non Hodgkin lymphoma. Serum methotrexate levels reached 37 micromol/l, and remained higher than 1 micromol/l for more
Autor:
L N Igwemezie, Marc Bonnay, J.P. Armand, D Abigerges, B Winograd, L Schacter, M. de Forni, Guy G. Chabot, C Terret, Sanjeev Kaul, J Ropers
Publikováno v:
Journal of Clinical Oncology. 14:2020-2030
PURPOSE The purpose of this study was to determine the bioavailability (F) of etoposide (E;VP-16) after oral administration of the water-soluble prodrug etoposide phosphate (EP;BMY-40481) during a phase I trial in cancer patients. PATIENTS AND METHOD
Publikováno v:
Investigational New Drugs. 11:323-328
LY 186641 is a diarylsulfonylurea with a broad spectrum antitumor activity against both murine and human solid tumors. We report here the results of a phase II trial of LY 186641 in advanced renal cell adenocarcinoma. The drug was administered orally
Autor:
Nancy Nader, Agnès Emptoz-Bonneton, Gérald Raverot, Michel Pugeat, Marc Bonnay, Henri Déchaud, Eric Baudin
Publikováno v:
The Journal of clinical endocrinology and metabolism. 91(6)
Side effects of mitotane (o,p'-DDD) have suggested estrogenic effects.The objective of the study was to explore o,p'-DDD potential estrogenic effect on SHBG and corticosteroid-binding globulin (CBG).Human hepatoma cell lines (HepG2), lacking estrogen
Autor:
Michel Ducreux, Marc Bonnay, Olivier Rixe, Radan Dzodic, Jean-Nicolas Munck, Alain Gouyette, Gonzalo Gomez-Abuin, Philippe Rougier, Patrice Ardouin
Publikováno v:
Anti-cancer drugs. 15(6)
The aim of this study was to compare intra-arterial hepatic administration (IAH) versus i.v. administration of oxaliplatin and cisplatin in a VX2 tumor model in rabbits. VX2 tumors were implanted in the livers of White New Zealand female rabbits and
Autor:
Jean-Charles Soria, Marc Bonnay, Mark A. Smith, Pierre Ruffié, A. Fandi, Catherine Hill, Jean-Pierre Armand, Karim Fizazi, Marc Poterre, Catherine Daniel, Michel Ducreux
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(11)
PURPOSE: To determine the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of the raltitrexed plus oxaliplatin combination regimen, to explore its safety and pharmacokinetics, and to assess its antitumor activity in patients with